High materiality8/10
Relmada Therapeutics initiated with a Buy at H.C. Wainwright
Why it may matterVerify against the original reporting
very_bullish
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
H.C. Wainwright initiates Relmada Therapeutics with a Buy rating and a $12 target; current price around $6.60, implying substantial upside.
- H.C. Wainwright initiates Relmada with a Buy and $12 target; current price $6.60.
Key facts
- 01
Target: $12
- 02
Posted price: $6.6
- 03
Analyst firm: H.C. Wainwright
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.